SG/PUT/MODERNA/140/0.1/21.03.25 | Market Closed - Börse Stuttgart 03:50:13 2024-07-01 pm EDT | ||
| 3.29 EUR | +4.78% |
|
| Current month | +4.78% | ||
| 1 month | +53.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 3.29 | +4.78% |
| 24-06-28 | 3.14 | +4.67% |
| 24-06-27 | 3 | +1.01% |
| 24-06-26 | 2.97 | +25.85% |
| 24-06-25 | 2.36 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 03:50 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SY0NV0 |
| ISIN | DE000SY0NV05 |
| Date issued | 2024-05-21 |
| Strike | 140 $ |
| Maturity | 2025-03-21 (263 Days) |
| Parity | 10 : 1 |
| Emission price | 2.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.34 € |
|---|---|
| Lowest since issue | 1.55 € |
| Spread | 0.02 € |
| Spread % | 0.60% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116
USD
Average target price
145.9
USD
Spread / Average Target
+25.79%
- Stock Market
- Warrants
- Warrant
